TY - JOUR
T1 - No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors
AU - Serretti, Alessandro
AU - Zanardi, Raffaella
AU - Cusin, Cristina
AU - Rossini, David
AU - Lilli, Roberta
AU - Lorenzi, Cristina
AU - Lattuada, Enrico
AU - Smeraldi, Enrico
PY - 2001/11/30
Y1 - 2001/11/30
N2 - The possible association of the dopamine receptor D2 (Ser 311Cys) and D4 exon 3 (48 base pair repeat) gene variants with the antidepressant activity of selective serotonin reuptake inhibitors (SSRIs) was investigated in a sample of 364 inpatients affected by a major depressive episode treated with fluvoxamine, 300 mg/day (n=266), or paroxetine, 20-40 mg/day (n=98). The severity of depressive symptoms was assessed weekly with the Hamilton Rating Scale for Depression. Dopamine receptor D2 (DRD2) and dopamine receptor D4 (DRD4) allelic variants were determined in each subject by polymerase chain reaction. We observed that DRD2 and DRD4 variants were not associated with response to SSRI treatment. Possible stratification factors, such as sex, diagnosis, presence of psychotic features, depressive symptoms at baseline, paroxetine and fluvoxamine plasma levels, and pindolol augmentation did not significantly influence the observed results. The investigated DRD2 and DRD4 gene variants therefore do not seem to play a major role in the antidepressant activity of SSRIs, at least in the present sample.
AB - The possible association of the dopamine receptor D2 (Ser 311Cys) and D4 exon 3 (48 base pair repeat) gene variants with the antidepressant activity of selective serotonin reuptake inhibitors (SSRIs) was investigated in a sample of 364 inpatients affected by a major depressive episode treated with fluvoxamine, 300 mg/day (n=266), or paroxetine, 20-40 mg/day (n=98). The severity of depressive symptoms was assessed weekly with the Hamilton Rating Scale for Depression. Dopamine receptor D2 (DRD2) and dopamine receptor D4 (DRD4) allelic variants were determined in each subject by polymerase chain reaction. We observed that DRD2 and DRD4 variants were not associated with response to SSRI treatment. Possible stratification factors, such as sex, diagnosis, presence of psychotic features, depressive symptoms at baseline, paroxetine and fluvoxamine plasma levels, and pindolol augmentation did not significantly influence the observed results. The investigated DRD2 and DRD4 gene variants therefore do not seem to play a major role in the antidepressant activity of SSRIs, at least in the present sample.
KW - Antidepressant treatment
KW - Fluvoxamine
KW - Mood disorders
KW - Paroxetine
KW - Pharmacogenetics
KW - Pindolol
UR - http://www.scopus.com/inward/record.url?scp=0035976689&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035976689&partnerID=8YFLogxK
U2 - 10.1016/S0165-1781(01)00324-9
DO - 10.1016/S0165-1781(01)00324-9
M3 - Article
C2 - 11728608
AN - SCOPUS:0035976689
VL - 104
SP - 195
EP - 203
JO - Psychiatry Research
JF - Psychiatry Research
SN - 0165-1781
IS - 3
ER -